Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy

New strategies are needed to improve the treatment of patients with breast cancer. Oncolytic virotherapy is a promising new tool for cancer treatment but still has a limited overall durable anti-tumor response. A novel replicable recombinant oncolytic herpes simplex virus type 1 called VG161 has been developed and has demonstrated anti-tumor effects in several cancers. Here, we explored the efficacy and the anti-tumor immune response of VG161 co-treatment with paclitaxel (PTX) which as a novel oncolytic viral immunotherapy for breast cancer.

改善乳腺癌患者的治疗亟需新的策略。溶瘤病毒疗法（Oncolytic virotherapy）是一种颇具前景的癌症治疗新手段，但整体持久抗肿瘤应答的效果仍较为有限。一种名为VG161的新型可复制重组1型单纯疱疹溶瘤病毒已被开发，并在多种癌症中展现出抗肿瘤效果。本研究探究了VG161与紫杉醇（paclitaxel, PTX）联合治疗的疗效及其抗肿瘤免疫应答，以此作为一种针对乳腺癌的新型溶瘤病毒免疫治疗方案。